Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Dinoprostone | hsa00310 | Lysine degradation | 6.96E-03 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Dinoprostone | hsa00515 | Mannose type O-glycan biosynthesis | 4.96E-02 | 1 | O75072 | FCMD | More | | Dinoprostone | hsa00620 | Pyruvate metabolism | 2.18E-02 | 2 | P40925, P51648 | MDH1, ALDH3A2 | More | | Dinoprostone | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.40E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Dinoprostone | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Dinoprostone | hsa03008 | Ribosome biogenesis in eukaryotes | 2.52E-02 | 3 | P78345, O15381, Q9GZY0 | RPP38, NVL, NXF2; NXF2B | More | | Dinoprostone | hsa03013 | RNA transport | 7.27E-03 | 12 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, EIF4A2, TACC3, FXR1 | More | | Dinoprostone | hsa03040 | Spliceosome | 3.37E-05 | 11 | Q14562, O43143, O60508, Q99633, P26368, Q13595, Q01130, Q13243, Q9UMS4, P11142, O43447 | DHX8, DHX15, CDC40, PRPF18, U2AF2, TRA2A, SFRS2, SFRS5, PRPF19, HSPA8, PPIH | More | | Dinoprostone | hsa03450 | Non-homologous end-joining | 4.96E-02 | 1 | Q9NP87 | POLM | More | | Dinoprostone | hsa04015 | Rap1 signaling pathway | 1.58E-02 | 6 | P20827, P49767, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, ACTG1, F2R, CALM1, PRKCA | More | | Dinoprostone | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | Dinoprostone | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | Dinoprostone | hsa04071 | Sphingolipid signaling pathway | 4.46E-04 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Dinoprostone | hsa04141 | Protein processing in endoplasmic reticulum | 1.41E-02 | 4 | P30101, P60604, P11142, P08238 | PDIA3, UBE2G2, HSPA8, HSP90AB1 | More | | Dinoprostone | hsa04145 | Phagosome | 1.06E-03 | 11 | O75015, P63261, Q15080, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | FCGR3B, ACTG1, NCF4, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | Dinoprostone | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Dinoprostone | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | Dinoprostone | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Dinoprostone | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Dinoprostone | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | Dinoprostone | hsa04613 | Neutrophil extracellular trap formation | 1.05E-02 | 12 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q15080, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Dinoprostone | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Dinoprostone | hsa04720 | Long-term potentiation | 2.74E-03 | 4 | P17252, Q16566, P0DP23, O15399 | PRKCA, CAMK4, CALM1, GRIN2D | More | | Dinoprostone | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | Dinoprostone | hsa04730 | Long-term depression | 1.35E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Dinoprostone | hsa04912 | GnRH signaling pathway | 3.14E-03 | 5 | P17252, Q16539, Q9Y6R4, Q14643, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, PRKACB | More | | Dinoprostone | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Dinoprostone | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Dinoprostone | hsa04925 | Aldosterone synthesis and secretion | 7.20E-03 | 4 | P0DP23, P17252, Q16566, P23634 | CALM1, PRKCA, CAMK4, ATP2B4 | More | | Dinoprostone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.75E-02 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | | Dinoprostone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.36E-02 | 4 | Q13485, P10415, P49767, P17252 | SMAD4, BCL2, VEGFC, PRKCA | More | | Dinoprostone | hsa04970 | Salivary secretion | 3.55E-02 | 3 | P23634, P17252, P0DP23 | ATP2B4, PRKCA, CALM1 | More | | Dinoprostone | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | Dinoprostone | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Dinoprostone | hsa05012 | Parkinson disease | 2.31E-02 | 4 | P21796, P60604, Q71U36, Q13509 | VDAC1, UBE2G2, TUBA1A, TUBB3 | More | | Dinoprostone | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Dinoprostone | hsa05020 | Prion disease | 3.50E-02 | 4 | P11142, P21796, Q71U36, Q13509 | HSPA8, VDAC1, TUBA1A, TUBB3 | More | | Dinoprostone | hsa05022 | Pathways of neurodegeneration - multiple diseases | 4.20E-02 | 5 | Q71U36, Q13509, P21796, P04628, P60604 | TUBA1A, TUBB3, VDAC1, WNT1, UBE2G2 | More | | Dinoprostone | hsa05031 | Amphetamine addiction | 1.49E-02 | 4 | O15399, P0DP23, Q16566, P17252 | GRIN2D, CALM1, CAMK4, PRKCA | More | | Dinoprostone | hsa05132 | Salmonella infection | 4.98E-02 | 6 | Q9UJU2, P63261, Q13489, P10415, Q13509, P68371 | LEF1, ACTG1, BIRC3, BCL2, TUBB3, TUBB2C | More | | Dinoprostone | hsa05133 | Pertussis | 2.52E-02 | 3 | P0DP23, P23528, P09871 | CALM1, CFL1, C1S | More | | Dinoprostone | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | Dinoprostone | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | Dinoprostone | hsa05200 | Pathways in cancer | 1.51E-02 | 12 | Q9UJU2, P17252, P43246, Q13485, P14923, P10415, Q13489, P49767, P25116, P78417, P0DP23, P01568 | LEF1, PRKCA, MSH2, SMAD4, JUP, BCL2, BIRC3, VEGFC, F2R, GSTO1, CALM1, IFNA21 | More | | Dinoprostone | hsa05202 | Transcriptional misregulation in cancer | 2.48E-03 | 13 | Q12778, Q15532, P41732, P14780, P27930, Q16548, Q13489, O15550, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, BCL2A1, BIRC3, UTX, BMI1, MPO, ELA2, BCL11B, GADD45A | More | | Dinoprostone | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | Dinoprostone | hsa05214 | Glioma | 3.55E-02 | 3 | P0DP23, Q16566, P17252 | CALM1, CAMK4, PRKCA | More | | Dinoprostone | hsa05321 | Inflammatory bowel disease | 3.69E-02 | 4 | O60603, P13765, Q14765, P23771 | TLR2, HLA-DOB, STAT4, GATA3 | More | | Dinoprostone | hsa05332 | Graft-versus-host disease | 1.32E-02 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | | Dinoprostone | hsa05418 | Fluid shear stress and atherosclerosis | 2.31E-02 | 5 | P78417, P63261, P10415, P0DP23, Q92974 | GSTO1, ACTG1, BCL2, CALM1, ARHGEF2 | More | | |